Volume 2.38 | Sep 26

Pulmonary Cell News 2.38 September 26, 2013
Pulmonary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Pulmonary Cell News on Twitter
 
TOP STORY
Lung Epithelial Branching Program Antagonizes Alveolar Differentiation
Scientists showed that an epithelial branching morphogenesis program antagonizes alveolar differentiation in the mouse lung. They found a negative correlation between branching morphogenesis and alveolar differentiation temporally, spatially, and evolutionarily. [Proc Natl Acad Sci USA] Abstract
Download a White Paper Describing the CFU Assay for Preclinical Toxicity Testing
 
PUBLICATIONS (Ranked by impact factor of the journal)
Soy Biodiesel and Petrodiesel Emissions Differ in Size, Chemical Composition and Stimulation of Inflammatory Responses in Cells and Animals
Researchers demonstrated that particulate matter generated by combustion of the two fuels induced different responses in in vitro and in vivo models. [Environ Sci Technol] Abstract

Curcumin Prevents Replication of Respiratory Syncytial Virus and the Epithelial Responses to it in Human Nasal Epithelial Cells
Researchers investigated the effects of the nuclear factor kappa B in human nasal epithelial cells infected with respiratory syncytial virus (RSV). Curcumin prevented the replication and budding of RSV and the epithelial responses to it without cytotoxicity. [PLoS One] Full Article

Mitochondrial Fragmentation in Cigarette Smoke Induced-Bronchial Epithelial Cell Senescence
Mitochondria in bronchial epithelial cells were prone to be more fragmented in chronic obstructive pulmonary disease lung tissues. Cigarette smoke extract induced mitochondrial fragmentation and mitochondrial reactive oxygen species production, which were responsible for acceleration of cellular senescence in human bronchial epithelial cells. [Am J Physiol Lung Cell Mol Physiol] Abstract

Metabolic Shift in Lung Alveolar Cell Mitochondria following Acrolein Exposure
Researchers examined the role of acrolein in altering mitochondrial function and metabolism in lung specific cells. Low-dose acrolein exposure decreased mitochondrial respiration in a dose-dependent manner due to alteration in the metabolism of glucose in three cell types. [Am J Physiol Lung Cell Mol Physiol] Abstract

Respiratory Syncytial Virus Infection Disrupts Monolayer Integrity and Function in Cystic Fibrosis Airway Cells
Researchers examined respiratory syncytial virus (RSV) infection in immortalized bronchial epithelial cells expressing wild-type or F508del cystic fibrosis transmembrane conductance regulator, for monolayer integrity and RSV replication. [Viruses] Abstract | Full Article

LUNG CANCER

The HDAC Inhibitor, MPT0E028, Enhances Erlotinib-Induced Cell Death in EGFR-TKI-Resistant NSCLC Cells
Researchers combined the histone deacetylase (HDAC) inhibitor, MPT0E028, with erlotinib in an effort to increase their antitumor effects in erlotinib-resistant lung adenocarcinoma cells. This combined treatment yielded significant growth inhibition, induced the expression of apoptotic proteins, increased the levels of acetylated histone H3, and showed synergistic effects in vitro and in vivo. [Cell Death Dis] Full Article

Orai3 Constitutes a Native Store-Operated Calcium Entry that Regulates Non-Small Cell Lung Adenocarcinoma Cell Proliferation
Scientists investigated the expression and the role of Orai3 in cell proliferation in non-small cell lung cancer. They showed that Orai3 is over-expressed in cancer tissues as compared to the non-tumoral ones. [PLoS One] Abstract

Induction of Apoptosis and Cell Cycle Arrest in A549 Human Lung Adenocarcinoma Cells by Surface Encapping Selenium Nanoparticles: An Effect Enhanced by Polysaccharides-Protein Complexes from Polyporus rhinocerus
Exposure to Polyporus rhinocerus water-soluble polysaccharides-protein complexes-selenium nanoparticles significantly inhibited the growth of A549 cells through induction of apoptosis and G2/M phase arrest supported by an increase of sub-G1 and G2/M phase cell populations, DNA fragmentation and chromatin condensation. [J Agric Food Chem] Abstract

Linobiflavonoid Inhibits Human Lung Adenocarcinoma A549 Cells: Effect on Tubulin Protein
The antitumor bioactivities of linobiflavonoid were studied through evaluating its in vitro cytotoxicity against several cell lines, with the aid of 3-(4,5-dimethylthiazolyl)-3,5-diphenytetrazolium bromide assay. Researchers found that linobiflavonoid showed more notable inhibiting activity against A549 cells. [Mol Biol Rep] Abstract

Selective Modulation of MHC Class II Chaperons by a Novel IFN-γ-Inducible Class II Transactivator Variant in Lung Adenocarcinoma A549 Cells
Unlike class II transactivator (CIITA)-TAG, CIITAΔE7 is expressed more abundantly in lung adenocarcinoma A549 cells than in the non-transformed counterpart BEAS-2B cells following interferon (IFN)-γ stimulation. [Biochem Biophys Res Commun] Abstract

Model the Human Respiratory Epithelium with PneumaCult™-ALI. Click to View Data.
 
REVIEWS
Pathogenesis of Idiopathic Pulmonary Fibrosis
Although an understanding of the pathogenesis of idiopathic pulmonary fibrosis (IPF) is incomplete, recent advances delineating specific clinical and pathologic features of IPF have led to better definition of the molecular pathways that are pathologically activated in the disease. The authors highlight several of these advances, with a focus on genetic predisposition to IPF and how genetic changes, which occur primarily in epithelial cells, lead to activation of profibrotic pathways in epithelial cells. [Annu Rev Pathol] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.
 
INDUSTRY NEWS
Leicester Leads Two Groundbreaking Trials into Treatments for Asbestos-Related Cancer
Professor Dean Fennell, of the University’s Department of Cancer Studies and Molecular Medicine, is leading two groundbreaking trials into mesothelioma – a form of lung cancer strongly linked with exposure to asbestos. [University of Leicester] Press Release

Verastem Initiates Phase II Trial of Defactinib in Lung Cancer
Verastem, Inc. focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase II trial of defactinib, a potent inhibitor of focal adhesion kinase, in KRAS-mutated non-small cell lung cancer. [Verastem, Inc.] Press Release

Oncothyreon Announces Merck Serono Decision to Continue the Development of Tecemotide in Stage III Non-Small Cell Lung Cancer
Oncothyreon Inc. announced that Merck Serono has decided to continue clinical development of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide. Merck Serono, which is developing tecemotide under a license agreement with Oncothyreon, will conduct a new Phase III trial called START2 for patients with unresectable, locally advanced Stage III non-small cell lung cancer. [Oncothyreon Inc.]
Press Release

Infinity Reports Topline Data from Phase II Study of Retaspimycin Hydrochloride, Its Hsp90 Inhibitor, in Patients with Non-Small Cell Lung Cancer
Infinity Pharmaceuticals, Inc. announced topline data from its Phase II study of retaspimycin hydrochloride, a potent and selective heat shock protein 90 (Hsp90) inhibitor, in patients with non-small cell lung cancer who had a history of smoking. [Infinity Pharmaceuticals, Inc.] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUORTM can help.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Keystone Symposia: Pathogenesis of Respiratory Viruses
January 19-24, 2014
Keystone, United States

Visit our events page to see a complete list of events in the pulmonary cell community.
 
JOB OPPORTUNITIES
NEW PhD Studentship Opportunity – Human Pulmonary Vascular Disease (University College Dublin)

Research Specialist – Lung Cancer (University of Illinois)

Postdoctoral Fellow – Lung Research (Brigham & Women’s Hospital – Harvard Medical School)

Postdoctoral Research Candidate – Chronic Lung Diseases (European Respiratory Society / Marie Curie)

Postdoctoral Research Position – Molecular and Cellular Mechanism of Pulmonary Vascular Inflammation and Dysfunction (University of Oklahoma Health Sciences Center)

Postdoctoral Position – Cardiopulmonary Molecular Biology (Hannover Medical School)

Postdoctoral Researcher – Respiratory Diseases Research (Boehringer Ingelheim Pharma GmbH & Co. KG)

Postdoctoral Associate – Lung Cancer (Yale Cancer Center)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Technologist – Mesenchymal Cell Research (STEMCELL Technologies Inc.)

Research Technologist – Cell Culture Media & Matrices (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Quality Control Analyst – Media (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Learn more about Pulmonary Cell News: Archives | Events | Contact Us